|
US6403597B1
(en)
*
|
1997-10-28 |
2002-06-11 |
Vivus, Inc. |
Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
|
|
US20040014761A1
(en)
*
|
1997-10-28 |
2004-01-22 |
Place Virgil A. |
Treatment of female sexual dysfunction with phosphodiesterase inhibitors
|
|
CA2309332C
(en)
*
|
1997-11-12 |
2002-12-03 |
Bayer Aktiengesellschaft |
2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
|
|
DE19827640A1
(de)
|
1998-06-20 |
1999-12-23 |
Bayer Ag |
7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
|
|
US7235625B2
(en)
|
1999-06-29 |
2007-06-26 |
Palatin Technologies, Inc. |
Multiple agent therapy for sexual dysfunction
|
|
DE19944161A1
(de)
*
|
1999-09-15 |
2001-03-22 |
Bayer Ag |
Neue Kombination zur Behandlung von sexueller Dysfunktion
|
|
CA2323008C
(en)
|
1999-10-11 |
2005-07-12 |
Pfizer Inc. |
Pharmaceutically active compounds
|
|
US20040254153A1
(en)
*
|
1999-11-08 |
2004-12-16 |
Pfizer Inc |
Compounds for the treatment of female sexual dysfunction
|
|
IL139457A0
(en)
*
|
1999-11-08 |
2001-11-25 |
Pfizer |
Compounds for the treatment of female sexual dysfunction
|
|
AU2365001A
(en)
|
1999-12-24 |
2001-07-09 |
Bayer Aktiengesellschaft |
Isoxazolo pyrimidinones and the use thereof
|
|
PL356848A1
(en)
*
|
1999-12-24 |
2004-07-12 |
Bayer Aktiengesellschaft |
Novel imidazo[1,3,5]triazinones and the use thereof
|
|
WO2001047929A1
(de)
*
|
1999-12-24 |
2001-07-05 |
Bayer Aktiengesellschaft |
Triazolotriazinone und ihre verwendung
|
|
DE10010067A1
(de)
|
2000-03-02 |
2001-09-06 |
Bayer Ag |
Neue Imidazotriazinone und ihre Verwendung
|
|
EP1278522B1
(en)
|
2000-04-19 |
2006-10-25 |
Lilly Icos LLC |
Pde-v inhibitors for treatment of parkinson's disease
|
|
US6821978B2
(en)
*
|
2000-09-19 |
2004-11-23 |
Schering Corporation |
Xanthine phosphodiesterase V inhibitors
|
|
MXPA03002813A
(es)
*
|
2000-09-29 |
2003-10-15 |
Glaxo Group Ltd |
Compuestos utiles en el tratamiento de enfermedades inflamatorias.
|
|
US6548508B2
(en)
|
2000-10-20 |
2003-04-15 |
Pfizer, Inc. |
Use of PDE V inhibitors for improved fecundity in mammals
|
|
US20020091129A1
(en)
*
|
2000-11-20 |
2002-07-11 |
Mitradev Boolell |
Treatment of premature ejaculation
|
|
DE10063108A1
(de)
*
|
2000-12-18 |
2002-06-20 |
Bayer Ag |
Verfahren zur Herstellung von Sulfonamid-substituierten Imidazotriazinonen
|
|
DE10063106A1
(de)
*
|
2000-12-18 |
2002-06-20 |
Bayer Ag |
Verfahren zur Herstellung von 2-(2-Ethoxyphenyl)-substituierten Imidazotriazinonen
|
|
DE10064105A1
(de)
*
|
2000-12-21 |
2002-06-27 |
Bayer Ag |
Neue Substituierte Imidazotriazinone
|
|
AU2002226633A1
(en)
*
|
2001-02-02 |
2002-08-12 |
Pfizer Limited |
Treatment of diabetes mellitus using vardenafil
|
|
DE10107639A1
(de)
*
|
2001-02-15 |
2002-08-22 |
Bayer Ag |
2-Alkoxyphenyl-substituierte Imidazotriazinone
|
|
DE10108752A1
(de)
*
|
2001-02-23 |
2002-09-05 |
Bayer Ag |
Neue Substituierte Imidazotriazinone
|
|
GB0107751D0
(en)
*
|
2001-03-28 |
2001-05-16 |
Pfizer Ltd |
Pharmaceutically active compounds
|
|
DE10118306A1
(de)
|
2001-04-12 |
2002-10-17 |
Bayer Ag |
Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
|
|
MXPA03010119A
(es)
*
|
2001-05-09 |
2005-03-07 |
Bayer Healthcare Ag |
Nuevo uso de imidazotriazinonas 2-fenilo sustituidas.
|
|
US7090830B2
(en)
|
2001-05-24 |
2006-08-15 |
Alexza Pharmaceuticals, Inc. |
Drug condensation aerosols and kits
|
|
US7585493B2
(en)
|
2001-05-24 |
2009-09-08 |
Alexza Pharmaceuticals, Inc. |
Thin-film drug delivery article and method of use
|
|
US20030051728A1
(en)
|
2001-06-05 |
2003-03-20 |
Lloyd Peter M. |
Method and device for delivering a physiologically active compound
|
|
US7458374B2
(en)
|
2002-05-13 |
2008-12-02 |
Alexza Pharmaceuticals, Inc. |
Method and apparatus for vaporizing a compound
|
|
US20070122353A1
(en)
|
2001-05-24 |
2007-05-31 |
Hale Ron L |
Drug condensation aerosols and kits
|
|
US7087605B2
(en)
|
2001-06-01 |
2006-08-08 |
Bayer Aktiengesellschaft |
5-Ethyl-imidazotriazinones
|
|
GB0113344D0
(en)
*
|
2001-06-01 |
2001-07-25 |
Bayer Ag |
Novel heterocycles 3
|
|
DE10130167A1
(de)
|
2001-06-22 |
2003-01-02 |
Bayer Ag |
Imidazotriazine
|
|
DE10135815A1
(de)
*
|
2001-07-23 |
2003-02-06 |
Bayer Ag |
Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
|
|
ES2302835T3
(es)
|
2001-08-28 |
2008-08-01 |
Schering Corporation |
Inhibidores de fosfodiesterasa v policiclicos de guanina.
|
|
WO2003042216A1
(en)
|
2001-11-09 |
2003-05-22 |
Schering Corporation |
Polycyclic guanine derivative phosphodiesterase v inhibitors
|
|
GB0129274D0
(en)
*
|
2001-12-06 |
2002-01-23 |
Pfizer Ltd |
Novel kit
|
|
CA2439784C
(en)
*
|
2001-12-13 |
2010-11-02 |
Daiichi Suntory Pharma Co., Ltd. |
Pyrazolopyrimidinone derivatives having pde7 inhibiting action
|
|
GB0130219D0
(en)
*
|
2001-12-18 |
2002-02-06 |
Pfizer Ltd |
Compounds for the treatment of sexual dysfunction
|
|
GB0209988D0
(en)
*
|
2002-05-01 |
2002-06-12 |
Bayer Ag |
Novel Heterocycles
|
|
DE10220570A1
(de)
|
2002-05-08 |
2003-11-20 |
Bayer Ag |
Carbamat-substituierte Pyrazolopyridine
|
|
WO2003101276A2
(en)
|
2002-05-22 |
2003-12-11 |
Virginia Commonwealth University |
Protective effects of pde-5 inhibitors
|
|
JP2005529927A
(ja)
*
|
2002-05-23 |
2005-10-06 |
ファイザー インコーポレイテッド |
新規な組み合わせ
|
|
SI1509525T1
(sl)
|
2002-05-31 |
2006-12-31 |
Schering Corp |
Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
|
|
GB0214784D0
(en)
*
|
2002-06-26 |
2002-08-07 |
Pfizer Ltd |
Novel combination
|
|
DE10229778A1
(de)
*
|
2002-07-03 |
2004-01-29 |
Bayer Ag |
Neue Verwendung von Imidazotriazinonen
|
|
DE10230605A1
(de)
|
2002-07-08 |
2004-01-29 |
Bayer Ag |
Substituierte Imidazotriazine
|
|
DE10232113A1
(de)
*
|
2002-07-16 |
2004-01-29 |
Bayer Ag |
Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
|
|
GB0219961D0
(en)
|
2002-08-28 |
2002-10-02 |
Pfizer Ltd |
Oxytocin inhibitors
|
|
US7323462B2
(en)
|
2002-12-10 |
2008-01-29 |
Pfizer Inc. |
Morpholine dopamine agonists
|
|
MXPA05006333A
(es)
|
2002-12-13 |
2005-08-26 |
Warner Lambert Co |
Metodo de tratamiento.
|
|
WO2004087652A2
(en)
*
|
2003-04-01 |
2004-10-14 |
Smithkline Beecham Corporation |
Imidazotriazine compounds
|
|
AU2004234158B2
(en)
|
2003-04-29 |
2010-01-28 |
Pfizer Inc. |
5,7-diaminopyrazolo[4,3-D]pyrimidines useful in the treatment of hypertension
|
|
US20040220186A1
(en)
*
|
2003-04-30 |
2004-11-04 |
Pfizer Inc. |
PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
|
|
WO2004104493A2
(en)
|
2003-05-21 |
2004-12-02 |
Alexza Pharmaceuticals, Inc. |
Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same
|
|
GEP20084342B
(en)
|
2003-05-22 |
2008-03-25 |
|
Composition comprising a pde4 inhibitor and a pde5 inhibitor
|
|
CN100374441C
(zh)
|
2003-06-06 |
2008-03-12 |
天津倍方科技发展有限公司 |
二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
|
|
JP2006219374A
(ja)
|
2003-06-13 |
2006-08-24 |
Daiichi Asubio Pharma Co Ltd |
Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
|
|
US20050079548A1
(en)
*
|
2003-07-07 |
2005-04-14 |
Plexxikon, Inc. |
Ligand development using PDE4B crystal structures
|
|
US7291640B2
(en)
*
|
2003-09-22 |
2007-11-06 |
Pfizer Inc. |
Substituted triazole derivatives as oxytocin antagonists
|
|
KR20060101762A
(ko)
*
|
2003-11-21 |
2006-09-26 |
쉐링 코포레이션 |
포스포디에스테라제 ｖ 억제제 제형
|
|
US7572799B2
(en)
*
|
2003-11-24 |
2009-08-11 |
Pfizer Inc |
Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
|
|
GB0327323D0
(en)
*
|
2003-11-24 |
2003-12-31 |
Pfizer Ltd |
Novel pharmaceuticals
|
|
WO2005079808A1
(en)
|
2004-01-22 |
2005-09-01 |
Pfizer Limited |
Triazole derivatives which inhibit vasopressin antagonistic activity
|
|
ATE417849T1
(de)
*
|
2004-04-07 |
2009-01-15 |
Pfizer |
Pyrazoloä4,3-düpyrimidine
|
|
DE102004023069A1
(de)
*
|
2004-05-11 |
2005-12-08 |
Bayer Healthcare Ag |
Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
|
|
US7540286B2
(en)
|
2004-06-03 |
2009-06-02 |
Alexza Pharmaceuticals, Inc. |
Multiple dose condensation aerosol devices and methods of forming condensation aerosols
|
|
JP2008501617A
(ja)
*
|
2004-06-11 |
2008-01-24 |
アスビオファーマ株式会社 |
Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
|
|
AU2004322756B2
(en)
|
2004-08-12 |
2011-04-14 |
Alexza Pharmaceuticals, Inc. |
Aerosol drug delivery device incorporating percussively activated heat packages
|
|
DE102005001989A1
(de)
*
|
2005-01-15 |
2006-07-20 |
Bayer Healthcare Ag |
Intravenöse Formulierungen von PDE-Inhibitoren
|
|
UA95604C2
(ru)
*
|
2005-02-18 |
2011-08-25 |
Сьёрфейс Лоджикс, Инк. |
Способ регулирования фармакокинетического и/или фармакодинамического свойства соединения
|
|
JP2008530247A
(ja)
*
|
2005-02-18 |
2008-08-07 |
サーフェイス ロジックス，インコーポレイティド |
薬物動態学的に改善された化合物
|
|
DE102005009241A1
(de)
|
2005-03-01 |
2006-09-07 |
Bayer Healthcare Ag |
Arzneiformen mit kontrollierter Bioverfügbarkeit
|
|
DE102005009240A1
(de)
*
|
2005-03-01 |
2006-09-07 |
Bayer Healthcare Ag |
Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
|
|
DE102005016345A1
(de)
*
|
2005-04-09 |
2006-10-12 |
Bayer Healthcare Ag |
Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
|
|
CN102614176A
(zh)
|
2005-04-19 |
2012-08-01 |
奈科明有限责任公司 |
用于治疗肺动脉高血压的罗氟司特
|
|
US8227475B2
(en)
|
2005-05-12 |
2012-07-24 |
Pfizer Inc. |
Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
|
|
WO2006127368A2
(en)
*
|
2005-05-20 |
2006-11-30 |
Lexicon Genetics Incorporated |
Methods for synthesizing imidazotriazinones
|
|
US20070010525A1
(en)
*
|
2005-06-27 |
2007-01-11 |
Meyer Jackson |
Method and compositions for modulating neuropeptide hormone secretion
|
|
CA2618103A1
(en)
*
|
2005-08-10 |
2007-02-15 |
Pfizer Limited |
Substituted triazole derivatives as oxytocin antagonists
|
|
WO2007025177A2
(en)
|
2005-08-26 |
2007-03-01 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
EP2258358A3
(en)
|
2005-08-26 |
2011-09-07 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
|
RU2435588C2
(ru)
|
2005-09-29 |
2011-12-10 |
Байер Шеринг Фарма Акциенгезельшафт |
Ингибиторы фдэ и их комбинации для лечения урологических расстройств
|
|
US20070093493A1
(en)
*
|
2005-10-12 |
2007-04-26 |
Lilly Icos Llc |
Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
|
|
US7985756B2
(en)
|
2005-10-21 |
2011-07-26 |
Braincells Inc. |
Modulation of neurogenesis by PDE inhibition
|
|
US20070112017A1
(en)
|
2005-10-31 |
2007-05-17 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
PE20080109A1
(es)
*
|
2006-02-17 |
2008-04-01 |
Wyeth Corp |
N-sulfonilacion selectiva de alcoholes sustituidos con 2-aminotrifluoralquilo
|
|
JP2009528281A
(ja)
*
|
2006-02-17 |
2009-08-06 |
ワイス |
スルホンアミド置換アルコールおよびその中間体の調製方法
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
US7977478B2
(en)
*
|
2006-03-13 |
2011-07-12 |
Dr. Reddy's Laboratories Limited |
Polymorphic forms of vardenafil
|
|
HUE030920T2
(en)
*
|
2006-03-17 |
2017-06-28 |
Univ Johns Hopkins |
N-hydroxylsulfonamide derivatives as novel physiologically useful nitroxyl donors
|
|
US20080027072A1
(en)
*
|
2006-04-20 |
2008-01-31 |
Ampla Pharmaceuticals, Inc. |
Potentiation of MC4 receptor activity
|
|
AU2007249435A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 HT receptor mediated neurogenesis
|
|
EP2377531A2
(en)
|
2006-05-09 |
2011-10-19 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
RU2461542C2
(ru)
|
2006-06-27 |
2012-09-20 |
Сандоз Аг |
Новый способ получения соли
|
|
WO2008008398A2
(en)
*
|
2006-07-14 |
2008-01-17 |
Shionogi & Co., Ltd. |
Oxime compounds and the use thereof
|
|
CA2661483A1
(en)
*
|
2006-08-24 |
2008-02-28 |
Surface Logix, Inc. |
Pharmacokinetically improved 2-phenyl-substituted imidazotriazinone derivatives and their use
|
|
AR062501A1
(es)
|
2006-08-29 |
2008-11-12 |
Actelion Pharmaceuticals Ltd |
Composiciones terapeuticas
|
|
JP2010502722A
(ja)
|
2006-09-08 |
2010-01-28 |
ブレインセルス，インコーポレイティド |
４−アシルアミノピリジン誘導体を含む組み合わせ
|
|
DE102006043443A1
(de)
*
|
2006-09-15 |
2008-03-27 |
Bayer Healthcare Ag |
Neue aza-bicyclische Verbindungen und ihre Verwendung
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
US8314119B2
(en)
*
|
2006-11-06 |
2012-11-20 |
Abbvie Inc. |
Azaadamantane derivatives and methods of use
|
|
ES2544724T3
(es)
|
2006-12-12 |
2015-09-03 |
Gilead Sciences, Inc. |
Composición para tratar una hipertensión pulmonar
|
|
SG174079A1
(en)
*
|
2007-02-12 |
2011-09-29 |
Dmi Biosciences Inc |
Treatment of comorbid premature ejaculation and erectile dysfunction
|
|
WO2008100933A2
(en)
|
2007-02-12 |
2008-08-21 |
Dmi Biosciences, Inc. |
Reducing side effects of tramadol
|
|
US20080194529A1
(en)
*
|
2007-02-12 |
2008-08-14 |
Auspex Pharmaceuticals, Inc. |
HIGHLY SELECTIVE and LONG-ACTING PDE5 MODULATORS
|
|
EP2121088B1
(en)
|
2007-03-09 |
2016-07-13 |
Alexza Pharmaceuticals, Inc. |
Heating unit for use in a drug delivery device
|
|
DE102007027067A1
(de)
|
2007-06-12 |
2008-12-18 |
Ratiopharm Gmbh |
Verfahren zur Herstellung eines Arzneimittels enthaltend Vardenafil Hydrochlorid Trihydrat
|
|
KR20100029762A
(ko)
*
|
2007-06-13 |
2010-03-17 |
바이엘 쉐링 파마 악티엔게젤샤프트 |
청력 장애 치료용 ｐｄｅ 억제제
|
|
CN101965348B
(zh)
*
|
2007-09-06 |
2013-11-13 |
上海特化医药科技有限公司 |
伐地那非的制备方法及其中间体
|
|
WO2009082845A1
(en)
|
2007-12-28 |
2009-07-09 |
Topharman Shanghai Co., Ltd. |
N-{1-[3-(2-ethoxy-5-(4-ethylpiperazinyl)benzenesulfonyl)-4,5-dihydro-5-oxo-1,2,4-triazin-6-yl]ethyl}butyramide, the preparation method and use thereof
|
|
WO2009091777A1
(en)
*
|
2008-01-15 |
2009-07-23 |
Forest Laboratories Holdings Limited |
Nebivolol in the treatment of sexual dysfunction
|
|
DE102008063992A1
(de)
|
2008-12-19 |
2010-09-02 |
Lerner, Zinoviy, Dipl.-Ing. |
Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
|
|
EP2379076B1
(en)
|
2008-12-23 |
2014-11-12 |
The Trustees of Columbia University in the City of New York |
Phosphodiesterase inhibitors and uses thereof
|
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
GB0903493D0
(en)
|
2009-02-27 |
2009-04-08 |
Vantia Ltd |
New compounds
|
|
DE102009020888A1
(de)
|
2009-05-12 |
2010-11-18 |
Ratiopharm Gmbh |
Schmelztablette, enthaltend ein Vardenafil-Salz
|
|
AU2010280358A1
(en)
|
2009-08-07 |
2012-03-08 |
Ranbaxy Laboratories Limited |
Processes for the preparation of vardenafil
|
|
UY33041A
(es)
|
2009-11-27 |
2011-06-30 |
Bayer Schering Pharma Aktienegesellschaft |
Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
|
|
PE20121742A1
(es)
|
2009-11-27 |
2012-12-13 |
Adverio Pharma Gmbh |
PROCEDIMIENTO PARA LA PREPARACION DE {4,6-DIAMINO-2-[1-(2-FLUOROBENCIL)-1H-PIRAZOLO[3,4-b]PIRIDIN-3-IL]PIRIMIDIN-5-IL}METILCARBAMATO DE METILO Y SU PURIFICACION PARA SU USO COMO PRINCIPIO ACTIVO FARMACEUTICO
|
|
EP2517705B1
(en)
|
2009-12-21 |
2016-10-19 |
Acef S/A |
Cubebin as vasodilating agent in the therapy of erectile dysfunction
|
|
PL390079A1
(pl)
|
2009-12-30 |
2011-07-04 |
Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna |
Sposób otrzymywania wardenafilu i jego izolacji jako soli z kwasem cytrynowym oraz krystaliczna postać tej soli
|
|
WO2011126250A2
(ko)
|
2010-04-05 |
2011-10-13 |
에스케이케미칼 주식회사 |
Pde5 억제제를 함유하는 피부 주름 개선용 조성물
|
|
DE102010021637A1
(de)
|
2010-05-26 |
2011-12-01 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
|
|
CN102382129B
(zh)
*
|
2010-08-19 |
2014-02-26 |
山东轩竹医药科技有限公司 |
螺环取代的磷酸二酯酶抑制剂
|
|
CN102372730B
(zh)
*
|
2010-08-19 |
2014-03-26 |
山东轩竹医药科技有限公司 |
桥环取代的磷酸二酯酶抑制剂
|
|
DK2619208T3
(en)
|
2010-09-20 |
2017-01-30 |
Ironwood Pharmaceuticals Inc |
IMIDAZOTRIAZINON COMPOUNDS
|
|
AU2011305462B2
(en)
|
2010-09-23 |
2015-11-26 |
Abbvie Bahamas Ltd. |
Monohydrate of an azaadamantane derivative
|
|
EA201691759A1
(ru)
|
2010-10-15 |
2017-05-31 |
Джилид Сайэнс, Инк. |
Композиции и способы лечения легочной гипертензии
|
|
TWI462739B
(zh)
|
2010-11-02 |
2014-12-01 |
Univ Kaohsiung Medical |
Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
|
|
CN102134242B
(zh)
*
|
2011-01-21 |
2013-08-28 |
浙江大德药业集团有限公司 |
一种用于治疗阳痿的快速长效的化合物
|
|
JP2015531401A
(ja)
|
2011-10-10 |
2015-11-02 |
ハー・ルンドベック・アクチエゼルスカベット |
イミダゾピラジノン骨格を有するｐｄｅ９ｉ
|
|
AT512084A1
(de)
|
2011-10-20 |
2013-05-15 |
Univ Wien Tech |
Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
|
|
US9402877B2
(en)
|
2011-11-04 |
2016-08-02 |
Xion Pharmaceuticals Corporation |
Methods and compositions for oral administration of melanocortin receptor agonist compounds
|
|
CZ2011767A3
(cs)
*
|
2011-11-24 |
2013-06-05 |
Zentiva, K.S. |
Zpusob prípravy a izolace solí vardenafilu s kyselinami
|
|
US20150119399A1
(en)
|
2012-01-10 |
2015-04-30 |
President And Fellows Of Harvard College |
Beta-cell replication promoting compounds and methods of their use
|
|
WO2013109738A1
(en)
|
2012-01-17 |
2013-07-25 |
The Trustees Of Columbia University In The City Of New York |
Novel phosphodiesterase inhibitors and uses thereof
|
|
BR112014018199A8
(pt)
|
2012-01-26 |
2021-03-02 |
H Lundbeck As |
inibidores da pde9 com cadeia principal imidazo triazinona, composição farmacêutica que os compreende, uso dos referidos inibidores e processo para sua preparação
|
|
WO2013129889A2
(ko)
|
2012-02-28 |
2013-09-06 |
주식회사 서울제약 |
실데나필을 유효성분으로 함유하며 고미가 은폐된 고함량 속용필름
|
|
HK1206726A1
(en)
|
2012-03-19 |
2016-01-15 |
Ironwood Pharmaceuticals, Inc. |
Imidazotriazinone compounds
|
|
CN103374002B
(zh)
*
|
2012-04-19 |
2015-07-15 |
山东轩竹医药科技有限公司 |
磷酸二酯酶-5抑制剂
|
|
CZ307091B6
(cs)
|
2012-09-14 |
2018-01-10 |
Zentiva, K.S. |
Stabilní farmaceutický přípravek obsahující Vardenafil hydrochlorid
|
|
EP2929886B1
(en)
|
2012-12-04 |
2021-11-24 |
Aribio Inc. |
Composition comprising phosphodiesterase type 5 inhibitor for inhibiting apoptosis of nerve cells
|
|
KR101953735B1
(ko)
|
2012-12-14 |
2019-03-04 |
한미약품 주식회사 |
포스포다이에스터라제-5 억제제를 포함하는 츄정
|
|
BR112015019571A2
(pt)
|
2013-02-21 |
2017-07-18 |
Adverio Pharma Gmbh |
formas de {4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridino-3-il]pirimidino-5-il}metilcarbamato de metila
|
|
CN104109164B
(zh)
*
|
2013-04-18 |
2016-05-25 |
广州朗圣药业有限公司 |
一种适合工业化的高纯度盐酸伐地那非三水合物的制备方法
|
|
WO2015009930A2
(en)
|
2013-07-17 |
2015-01-22 |
The Trustees Of Columbia University In The City Of New York |
Novel phosphodiesterase inhibitors and uses thereof
|
|
WO2015089105A1
(en)
|
2013-12-09 |
2015-06-18 |
Respira Therapeutics, Inc. |
Pde5 inhibitor powder formulations and methods relating thereto
|
|
PL223869B1
(pl)
|
2013-12-16 |
2016-11-30 |
Starogardzkie Zakłady Farm Polpharma Spółka Akcyjna |
Sposób otrzymywania wardenafilu i jego soli
|
|
KR101645652B1
(ko)
|
2014-11-03 |
2016-08-08 |
(주)퓨젠바이오농업회사법인 |
세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물
|
|
US10513524B2
(en)
|
2015-07-07 |
2019-12-24 |
H. Lundbeck A/S |
PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
|
|
WO2017085056A1
(en)
|
2015-11-16 |
2017-05-26 |
Topadur Pharma Ag |
2-phenyl-3,4-dihydropyrrolo[2,1 -f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof
|
|
WO2017168174A1
(en)
|
2016-04-02 |
2017-10-05 |
N4 Pharma Uk Limited |
New pharmaceutical forms of sildenafil
|
|
CN110381951A
(zh)
|
2016-12-14 |
2019-10-25 |
瑞必治公司 |
用于治疗肺性高血压和其他肺病症的方法及组合物
|
|
JP7182568B2
(ja)
|
2017-05-22 |
2022-12-02 |
トパドゥール ファーマ アーゲー |
新規二重作用モード可溶性グアニル酸シクラーゼ活性化因子およびホスホジエステラーゼ阻害剤ならびにその使用
|
|
CN107445964A
(zh)
*
|
2017-07-29 |
2017-12-08 |
合肥创新医药技术有限公司 |
一种盐酸伐地那非杂质的合成方法
|
|
RU2020123526A
(ru)
|
2017-12-20 |
2022-01-20 |
Клария Фарма Холдинг Аб |
Пленочная композиция, содержащая варденафил, способ ее получения и применение
|
|
KR102852740B1
(ko)
|
2018-02-02 |
2025-08-29 |
알렉스자 파마스티칼즈, 인크. |
전기적 응축 에어로졸 디바이스
|
|
CN112469413B
(zh)
|
2018-05-25 |
2024-01-12 |
伊马拉公司 |
6-[(3s,4s)-4-甲基-1-(嘧啶-2-基甲基)吡咯烷-3-基]-3-四氢吡喃-4-基-7h-咪唑并[1,5-a]吡嗪-8-酮的一水合物和结晶形态
|
|
CA3103716A1
(en)
|
2018-06-14 |
2019-12-19 |
Astrazeneca Uk Limited |
Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition
|
|
CA3103695A1
(en)
|
2018-06-14 |
2019-12-19 |
Astrazeneca Uk Limited |
Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition
|
|
CA3110680A1
(en)
|
2018-08-31 |
2020-03-05 |
Imara Inc. |
Pde9 inhibitors for treating sickle cell disease
|
|
CA3117068A1
(en)
*
|
2018-11-28 |
2020-06-04 |
Topadur Pharma Ag |
Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
|
|
EP3939954B1
(en)
|
2019-03-13 |
2025-07-23 |
Otsuka Pharmaceutical Co., Ltd. |
Method for introducing deuterated lower alkyl into amine moiety of compound containing secondary amine
|
|
US11590209B2
(en)
|
2020-01-21 |
2023-02-28 |
Palatin Technologies, Inc. |
Use of bremelanotide in patients with controlled hypertension
|
|
WO2021245192A1
(en)
|
2020-06-04 |
2021-12-09 |
Topadur Pharma Ag |
Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
|
|
AU2021396593A1
(en)
*
|
2020-12-11 |
2023-07-20 |
Ildong Pharmaceutical Co., Ltd. |
Novel compounds as androgen receptor and phosphodiesterase dual inhibitor
|
|
CN117177974A
(zh)
*
|
2021-04-21 |
2023-12-05 |
长春金赛药业有限责任公司 |
含咪唑稠环类衍生物、其制备方法及其在医药上的应用
|
|
CN114085225A
(zh)
*
|
2021-06-04 |
2022-02-25 |
广东西捷药业有限公司 |
一种伐地那非类似物及其合成方法和应用
|
|
JP2024536047A
(ja)
|
2021-09-29 |
2024-10-04 |
トパデュール ファルマ アーゲー |
２－フェニル－３，４－ジヒドロピロロ［２，ｌ－ｆ］［１，２，４］トリアジノン誘導体の局所組成物及びその使用
|
|
KR20230129639A
(ko)
|
2022-03-02 |
2023-09-11 |
연세대학교 산학협력단 |
이중작용 pde5 억제제/질산유기에스터의 국소 혈류 증진을 위한 경피 투약 형태
|
|
AU2023227111A1
(en)
|
2022-03-02 |
2024-07-25 |
Topadur Pharma Ag |
Topical compositions and uses therof
|
|
WO2024173675A1
(en)
|
2023-02-16 |
2024-08-22 |
University Of Rochester |
Improving glymphatic-lymphatic efflux
|